Prosekina E A, Shapkina V A, Karpov A E, Fedorutseva E Yu, Artemyeva A S
N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, Russia.
National Research Tomsk State University, Tomsk, Russia.
Arkh Patol. 2025;87(1):60-67. doi: 10.17116/patol20258701160.
Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) is an essential enzyme capable of degrading asymmetric dimethylarginine, which is an endogenous inhibitor of nitric oxide synthase. Increased expression of DDAH1 and subsequent increased NO production are associated with carcinogenesis. In particular, DDAH1 is involved in the creation of a vascular network by tumor cells, vasculogenic mimicry, which is closely associated with tumor progression and poor patient prognosis. This is the reason why DDAH1 may be a potential therapeutic target for the treatment of cancer.
二甲基精氨酸二甲胺水解酶1(DDAH1)是一种能够降解不对称二甲基精氨酸的关键酶,不对称二甲基精氨酸是一氧化氮合酶的内源性抑制剂。DDAH1表达增加及随后一氧化氮生成增加与肿瘤发生有关。特别是,DDAH1参与肿瘤细胞形成血管网络,即血管生成拟态,这与肿瘤进展和患者预后不良密切相关。这就是DDAH1可能成为癌症治疗潜在治疗靶点的原因。